CERA vs other ESA
Numbers of adverse events due to access thrombosis · patients with the anaemia of end‐stage kidney disease undergoing dialysis
CERA showed no clear difference in numbers of adverse events due to access thrombosis: CERA every 2… compared with other ESA (moderate certainty).
1 finding from 1 review
- Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in… 2014 · Cochrane Headline outcomes onlyRR 0.96 [0.56, 1.65]4 studies · 1341 participantsModerate